This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00378/identifier/chebi/
n25http://linked.opendata.cz/resource/drugbank/company/
n19http://linked.opendata.cz/resource/mesh/concept/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00378/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/mixture/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00378/identifier/pharmgkb/
n21http://bio2rdf.org/drugbank:
n8http://linked.opendata.cz/resource/drugbank/drug/DB00378/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00378/identifier/pubchem-substance/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00378/identifier/kegg-drug/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00378/identifier/iuphar/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00378/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/drug/DB00378/identifier/guide-to-pharmacology/
n18http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n17http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n22http://linked.opendata.cz/ontology/sukl/drug/
n23http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00378/identifier/chemspider/

Statements

Subject Item
n2:DB00378
rdf:type
n3:Drug
n3:description
A synthetic progestational hormone with no androgenic or estrogenic properties. Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation. [PubChem]
n3:generalReferences
# "Link":http://www.patient.co.uk/showdoc/30003042/
n3:group
approved withdrawn
n3:halfLife
Dydrogesterone: 5-7 hours, 20-dihydrodydrogesterone (DHD) metabolite: 14-17 hours
n3:indication
Used to treat irregular duration of cycles and irregular occurrence and duration of periods caused by progesterone deficiency. Also used to prevent natural abortion in patients who have a history of habitual abortions.
n3:manufacturer
n25:271B643E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n21:DB00378 n24:DB00378
dcterms:title
Dydrogesterone
adms:identifier
n6:31527 n7:8699 n8:9051 n9:46506195 n10:2878 n11:D01217 n12:PA164745443 n13:DB00378 n14:Dydrogesterone n15:2878
n3:mechanismOfAction
Dydrogesterone is a progestogen that works by regulating the healthy growth and normal shedding of the womb lining by acting on progesterone receptors in the uterus.
n3:synonym
Dydrogesterone 6-Dehydro-retro-progesterone Dydrogestérone Didrogesterona delta(Sup 6)-retroprogesterone (9β,10α)-pregna-4,6-diene-3,20-dione Dydrogesteronum 10alpha-Isopregnenone delta(6)-Retroprogesterone Hydrogesterone Retro-6-dehydroprogesterone Didrogesterone 9β,10α-pregna-4,6-diene-3,20-dione Hydrogestrone Gestatron Dydrogesterona Isopregnenone
n3:toxicity
No serious or unexpected toxicity has been observed with dydrogesterone. In acute toxicity studies, the LD50 doses in rats exceeded 4,640mg/kg for the oral route.
n3:mixture
n4:271B6437-363D-11E5-9242-09173F13E4C5 n4:271B6438-363D-11E5-9242-09173F13E4C5 n4:271B6435-363D-11E5-9242-09173F13E4C5 n4:271B6436-363D-11E5-9242-09173F13E4C5 n4:271B643D-363D-11E5-9242-09173F13E4C5 n4:271B643B-363D-11E5-9242-09173F13E4C5 n4:271B643C-363D-11E5-9242-09173F13E4C5 n4:271B6439-363D-11E5-9242-09173F13E4C5 n4:271B643A-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Reerink, E.H., Westerhof, P. and Scholer, H.F.L.; U.S. Patent 3,198,792; assigned to North American Philips Company, Inc.
n18:hasConcept
n19:M0006900
n3:IUPAC-Name
n17:271B6443-363D-11E5-9242-09173F13E4C5
n3:InChI
n17:271B6449-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n17:271B6448-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n17:271B6445-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n17:271B6446-363D-11E5-9242-09173F13E4C5
n3:SMILES
n17:271B6447-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n17:271B6441-363D-11E5-9242-09173F13E4C5
n3:logP
n17:271B645A-363D-11E5-9242-09173F13E4C5 n17:271B643F-363D-11E5-9242-09173F13E4C5 n17:271B6442-363D-11E5-9242-09173F13E4C5
n3:logS
n17:271B6440-363D-11E5-9242-09173F13E4C5
n22:hasATCCode
n23:G03DB01
n3:H-Bond-Acceptor-Count
n17:271B644F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n17:271B6450-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n17:271B644A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n17:271B644B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n17:271B644D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n17:271B644C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n17:271B644E-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed in the gastrointestinal tract with a bioavailability of 28%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
152-62-5
n3:category
n3:Bioavailability
n17:271B6455-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n17:271B6457-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n17:271B6458-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n17:271B6459-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n17:271B6454-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n17:271B6453-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n17:271B6456-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n17:271B6444-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n17:271B6451-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n17:271B6452-363D-11E5-9242-09173F13E4C5